<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256944</url>
  </required_header>
  <id_info>
    <org_study_id>WFH-PCOS-99041</org_study_id>
    <nct_id>NCT01256944</nct_id>
  </id_info>
  <brief_title>To Study Polycystic Ovary Syndrome in Taiwanese Women</brief_title>
  <official_title>To Study Polycystic Ovary Syndrome in Taiwanese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is an extremely common disorder in women of reproductive
      age. Diagnosis of PCOS is principally based on clinical and physical findings. Diagnostic
      criteria and PCOS definitions used by clinicians and researchers are almost as heterogeneous
      as the syndrome. Of those diagnosed with PCOS using the 2003 Rotterdam criteria, 61%
      fulfilled 1990 NIH criteria for unexplained hyperandrogenic chronic anovulation. The patient
      populations with the new phenotypes had less severe ovulatory dysfunction and less androgen
      excess than patients diagnosed using the 1990 NIH criteria. These findings might be common
      across all female populations with PCOS, whether in Oriental or Occidental countries. Data
      for clinical hyperandrogenism indicated that the prevalence of hirsutism in Taiwanese PCOS
      women is lower than that for Caucasians/Western women.

      The extent of metabolic abnormalities in women with PCOS may vary with phenotype, age and
      ethnicity. Obesity represents a major risk factor for metabolic syndrome and insulin
      resistance. Approximately 40-50% of all women with PCOS are overweight or obese. Obese
      subjects with PCOS had a higher risk of developing oligomenorrhea, amenorrhea and biochemical
      hyperandrogenemia than non-obese women with PCOS. Moreover, obese women with PCOS had
      significantly more severe insulin resistance, lower serum LH levels, and lower LH-to-FSH
      ratios than non-obese women with PCOS. PCOS women in Taiwan presented with higher LH-to-FSH
      ratio and lower insulin resistance than PCOS women in Western Countries. However, the average
      body mass index (BMI) was significantly lower in Taiwanese PCOS women than Western women,
      which might partially explain the difference between these two populations in terms of
      clinical and biochemical presentations.

      To further document the ethnic variation between women with PCOS in Taiwan and Western, the
      effect of obesity on the diagnosis and clinical presentations of PCOS-related syndromes
      should not be neglected in future studies. Therefore, the investigators plan to do this
      prospective study for evaluation the clinical and biochemical presentation of Taiwanese women
      with PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Method

        1. This study was approved by the Institutional Review Board of the Wan Fang Medical Center
           at Taipei Medical University (WF99041, approved August 2010) and performed at the
           Reproductive Endocrinology Clinic at the Wan Fang Medical Center from 31 August 2010 to
           31 August 2011. The following women were excluded: (i) women who had been diagnosed with
           hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital
           adrenal hyperplasia, androgen-secreting tumor,Cushing's syndrome, disorders of the
           uterus and chromosomal anomalies; (ii) women who were less than three years past
           menarche or who were older than 45 years; (iii) women who received hormones or
           medication for major medical diseases (diabetes or cardiovascular disease); and (iv)
           women who had had ovarian cysts or ovarian tumors identified by ultrasonographic
           examination.

        2. Statistical analysis: We used chi-squared and Fisher's exact tests to perform
           categorical comparisons and ANOVA to compare the continuous variables. The means of more
           than two groups were compared using one-way ANOVA and post hoc Dunnett's t-test with
           equal variances not assumed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>1 year</time_frame>
    <description>Using serum total testosterone to represent the severity of hyperandrogenism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>1 year</time_frame>
    <description>BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>1 year</time_frame>
    <description>A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Two Hour Glucose</measure>
    <time_frame>1 year</time_frame>
    <description>2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)</measure>
    <time_frame>1 year</time_frame>
    <description>HOMA-IR = [fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)]/405.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Hypercholesterolemia was defined as &gt;6 mmol / L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>1 year</time_frame>
    <description>Abnormal serum triglycerides defined as ≥ 1.7 mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL</measure>
    <time_frame>1 year</time_frame>
    <description>Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:
abdominal obesity (waist circumference &gt;80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL&lt;1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL</measure>
    <time_frame>1 year</time_frame>
    <description>Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).
Abnormal LDL was ≧4.14mmol/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impaired Glucose Tolerance</measure>
    <time_frame>1 years</time_frame>
    <description>Impaired glucose tolerance was defined as two hour glucose levels of 7.8-11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be &lt;7 mmol/L.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">290</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The normal reproductive-aged women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCOS</arm_group_label>
    <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Polycystic Ovary Syndrome(PCOS)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women at reproductive age

          -  women with PCOS and women without PCOS.

        Exclusion Criteria:

          -  young women who had their menarche less than 3 years

          -  women older than 45 years old, Amenorrhea of menopause, hyperglycemia,
             hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia,
             dystrophy, gonitis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-I Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University WanFang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Medical University-WanFang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <results_first_submitted>November 28, 2013</results_first_submitted>
  <results_first_submitted_qc>December 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2016</results_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University WanFang Hospital</investigator_affiliation>
    <investigator_full_name>Ming-I Hsu, MD</investigator_full_name>
    <investigator_title>Attending Doctor</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>DM</keyword>
  <keyword>Hypertension</keyword>
  <keyword>CVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>The normal women</description>
        </group>
        <group group_id="P2">
          <title>PCOS</title>
          <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>The normal women</description>
        </group>
        <group group_id="B2">
          <title>PCOS</title>
          <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years old</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="4.4"/>
                    <measurement group_id="B2" value="26.9" spread="5.8"/>
                    <measurement group_id="B3" value="27.68" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Testosterone</title>
        <description>Using serum total testosterone to represent the severity of hyperandrogenism.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone</title>
          <description>Using serum total testosterone to represent the severity of hyperandrogenism.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="2.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BMI</title>
        <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="5.2"/>
                    <measurement group_id="O2" value="25.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Insulin</title>
        <description>A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <description>A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.</description>
          <units>μIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="5.7"/>
                    <measurement group_id="O2" value="13.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose</title>
        <description>Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.0"/>
                    <measurement group_id="O2" value="5.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Two Hour Glucose</title>
        <description>2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Two Hour Glucose</title>
          <description>2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.1"/>
                    <measurement group_id="O2" value="6.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)</title>
        <description>HOMA-IR = [fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)]/405.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)</title>
          <description>HOMA-IR = [fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)]/405.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.3"/>
                    <measurement group_id="O2" value="3.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cholesterol</title>
        <description>Hypercholesterolemia was defined as &gt;6 mmol / L.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol</title>
          <description>Hypercholesterolemia was defined as &gt;6 mmol / L.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.8"/>
                    <measurement group_id="O2" value="4.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides</title>
        <description>Abnormal serum triglycerides defined as ≥ 1.7 mmol/L</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Abnormal serum triglycerides defined as ≥ 1.7 mmol/L</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.5"/>
                    <measurement group_id="O2" value="1.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HDL</title>
        <description>Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:
abdominal obesity (waist circumference &gt;80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL&lt;1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>HDL</title>
          <description>Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:
abdominal obesity (waist circumference &gt;80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL&lt;1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL</title>
        <description>Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).
Abnormal LDL was ≧4.14mmol/L.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>The normal women</description>
          </group>
          <group group_id="O2">
            <title>PCOS</title>
            <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
        </group_list>
        <measure>
          <title>LDL</title>
          <description>Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).
Abnormal LDL was ≧4.14mmol/L.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.6"/>
                    <measurement group_id="O2" value="3.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Impaired Glucose Tolerance</title>
        <description>Impaired glucose tolerance was defined as two hour glucose levels of 7.8–11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be &lt;7 mmol/L.</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese With PCOS</title>
            <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).
Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
          <group group_id="O2">
            <title>Obese With Control</title>
            <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).</description>
          </group>
          <group group_id="O3">
            <title>Non-obese With PCOS</title>
            <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI &lt; 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).
Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
          </group>
          <group group_id="O4">
            <title>Nonb-obese With Control</title>
            <description>BMI categorization was based on the WHO Asia–Pacific classification for obesity, which was defined as BMI &lt; 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).</description>
          </group>
        </group_list>
        <measure>
          <title>Impaired Glucose Tolerance</title>
          <description>Impaired glucose tolerance was defined as two hour glucose levels of 7.8–11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be &lt;7 mmol/L.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>The normal women</description>
        </group>
        <group group_id="E2">
          <title>PCOS</title>
          <description>Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ming-I Hsu</name_or_title>
      <organization>Taipei Medical University - WanFang Hospital</organization>
      <phone>886-2-2930-7930 ext 2508</phone>
      <email>hsumigni@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

